The FDA Sends A Complete Response Letter To Avenue Therapeutics For IV Tramadol

Avenue Therapeutics (NASDAQ: ATXI) (“Avenue”) is a company that develops intravenous Tramadol IV for the United States market, and it recently received its second CRL (Complete Response Letter) from the FDA regarding its New Drug Application which requested approval for Tramadol IV. The Complete Response Letter stated that the unpredictable […]


U.S. FDA Declines to Approve Avenue Therapeutics Inc’s (NASDAQ: ATXI) Painkiller Again, Shares Drop

The U.S. Food and Drug Administration has once again declined to approve Avenue Therapeutics Inc’s (NASDAQ: ATXI) painkiller tramadol noting that it was not safe for the intended population. The announcement saw Avenue’s share drop by 5% in premarket trading.  According to the FDA, intravenous (IV) tramadol showed delayed and […]